CoChat

O3‐04–05: Clinical trials of bapineuzumab, a beta‐amyloid‐targeted immunotherapy in patients with mild to moderate Alzheimer's disease

Grundman, Michael, Black, Ronald · 2008 · Alzheimer's & Dementia
Cited by 30

The DOI matches its Crossref record.

Abstract

Immunotherapy has been shown to reduce beta-amyloid (Aβ), a protein that accumulates in Alzheimer's disease (AD) brain and is central to the neuropathology of AD. Preclinical studies have shown that immunotherapy with antibodies raised to the N-terminus of Aβ reduce amyloid burden and have favorable effects on synaptic density and memory. A phase 1 study of bapineuzumab, a fully-humanized monoclonal antibody raised against the N-terminus of Aβ, demonstrated single dose safety and tolerability of bapineuzumab in patients with mild-to-moderate AD. Based on phase 1 results, a phase 2, multiple ascending dose study of bapineuzumab was initiated. This randomized, multicenter, double-blind study in patients with mild-to-moderate AD was designed to explore the potential efficacy and safety of bapineuzumab at various doses compared with placebo. Patients were randomized to receive either 0.15 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg bapineuzumab or placebo in a 1:1 fashion. Patients are being followed for 18 months to determine the safety of bapineuzumab, as well as bapineuzumab's efficacy as measured by cognitive measures (ADAS-Cog; NTB) and functional assessments (DAD). Additional analyses of brain volume by MRI, amyloid brain imaging, and measurement of cerebrospinal fluid Aβ and tau protein levels are planned. Information regarding the bapineuzumab development program will be presented.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2008.05.436

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 30

Metadata

Authors
Grundman, M., & Black, R.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2008-07
Volume
4
Issue
4S_Part_5
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2079845730
Cited by
30
References
0
FWCI
5.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: O3‐04–05: Clinical trials of bapineuzumab, a beta‐amyloid‐targeted immunotherapy in patients with mild to moderate Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2008.05.436
The paper
Grundman, M., & Black, R. (2008). O3‐04–05: Clinical trials of bapineuzumab, a beta‐amyloid‐targeted immunotherapy in patients with mild to moderate Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2008.05.436

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.